Emerging PET Radiotracer May Improve Detection of Coronary Artery Disease in Obese Patients
In a recent interview at the SNMMI conference, Krishna Patel, M.D., discussed the benefits of the PET perfusion radiotracer agent 18F-flurpiridaz and new research findings showing the agent’s increased sensitivity and specificity in diagnosing coronary artery disease in obese patients.
The use of conventional imaging for diagnosing coronary artery disease (CAD) in obese patients can be challenging. Attenuation artifacts can be problematic with single photon emission computed tomography (SPECT) and a lack of crisp image quality is an issue with coronary computed tomography angiography (CCTA) in this patient population, pointed out Krishna Patel, MD, in an interview at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
Higher radiation dosing is also a concern with both of the aforementioned modalities, noted Dr. Patel, an assistant professor of medicine (cardiology) and population health science and policy at Icahn School of Medicine at Mount Sinai.
Accordingly, Dr. Patel and colleagues examined the use of the positron emission tomography (PET) perfusion radiotracer agent 18F-flurpiridaz in comparison to 99mTc-SPECT for detecting CAD in a subgroup analysis involving 298 obese patients (mean age of 62.1) from a phase 3 trial.
The researchers found that among obese patients, 18F-flurpiridaz demonstrated higher sensitivity rates (76.9 percent versus 69.2 percent) and specificity rates (66.9 percent versus 61.9 percent) in comparison to 99mTc-SPECT. The use of 18F-flurpiridaz also reduced radiation exposure by one-third (6.2 mSv PET) in comparison to tetrofosmin SPECT (9.9 mSv) and by one-half in comparison to sestamibi SPECT (12.4 mSv), according to Dr. Patel and colleagues.
Dr. Patel, the director of cardiac PET at Mount Sinai Morningside in New York City, added that other key benefits of 18F-flurpiridaz include a longer half-life (110 minutes) than other PET perfusion tracer agents and unit dose availability, factors that may significantly expand access to stress cardiac PET myocardial perfusion imaging.
For more insights from Dr. Patel, watch the video below.
New Analysis Forecasts Substantial Cost Savings with the Use of Photon Counting CT for CCTA
March 8th 2025The use of ultra-high-resolution photon-counting CT in the evaluation of stable chest pain may significantly reduce follow-up tests and invasive coronary angiography (ICA) procedures, possibly resulting in millions in health-care cost savings, according to a cost-effectiveness analysis presented recently at the European Congress of Radiology.
Can Deep Learning Ultra-Fast bpMRI Have an Impact in Prostate Cancer Imaging?
March 3rd 2025A deep learning-enhanced ultra-fast bpMRI protocol offered similar sensitivity for csPCa as mpMRI with an 80 percent reduction in scan time, according to research findings presented at the European Congress of Radiology (ECR) conference.
ECR Mammography Study: Pre-Op CEM Detects 34 Percent More Multifocal Masses than Mammography
February 28th 2025In addition to contrast-enhanced mammography (CEM) demonstrating over a 90 percent detection rate for multifocal masses, researchers found that no significant difference between histological measurements and CEM, according to study findings presented at the European Congress of Radiology.
